Ruf Rainer G, Schultheiss Michael, Lichtenberger Anne, Karle Stephanie M, Zalewski Isabella, Mucha Bettina, Everding Anne Schulze, Neuhaus Thomas, Patzer Ludwig, Plank Christian, Haas Johannes P, Ozaltin Fatih, Imm Anita, Fuchshuber Arno, Bakkaloglu Aysin, Hildebrandt Friedhelm
Departments of Pediatrics and Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
Kidney Int. 2004 Aug;66(2):564-70. doi: 10.1111/j.1523-1755.2004.00775.x.
Nephrotic syndrome (NS) represents the association of proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Steroid-resistant nephrotic syndrome (SRNS) is defined by primary resistance to standard steroid therapy. It remains one of the most intractable causes for end-stage renal disease (ESRD) in the first two decades of life. Sporadic mutations in the Wilms' tumor suppressor gene WT1 have been found to be present in patients with SRNS in association with Wilms' tumor (WT) and urinary or genital malformations, as well as in patients with isolated SRNS.
To further evaluate the incidence of WT1 mutations in patients with NS we performed mutational analysis in 115 sporadic cases of SRNS and in 110 sporadic cases of steroid-sensitive nephrotic syndrome (SSNS) as a control group. Sixty out of 115 (52%) patients with sporadic SRNS were male, 55/115 (48%) were female. Sex genotype was verified by haplotype analysis. Mutational analysis was performed by direct sequencing and by denaturing high-performance liquid chromatography (DHPLC).
Mutations in WT1 were found in 3/60 (5%) male (sex genotype) cases and 5/55 (9%) female (sex genotype) cases of sporadic SRNS, and 0/110 (0%) sporadic cases of SSNS. One out of five female patients with mutations in WT1 developed a WT, 2/3 male patients presented with the association of urinary and genital malformations, 1/3 male patients presented with sexual reversal (female phenotype) and bilateral gonadoblastoma, and 4/5 female patients presented with isolated SRNS.
According to the data acquired in this study, patients presenting with a female phenotype and SRNS and male patients presenting with genital abnormalities should especially be screened to take advantage of the important genetic information on potential Wilms' tumor risk and differential therapy. This will also help to provide more data on the phenotype/genotype correlation in this patient population.
肾病综合征(NS)表现为蛋白尿、低白蛋白血症、水肿和高脂血症。激素抵抗型肾病综合征(SRNS)定义为对标准激素治疗原发抵抗。它仍然是生命最初二十年中终末期肾病(ESRD)最棘手的病因之一。已发现威尔姆斯肿瘤抑制基因WT1的散发性突变存在于患有SRNS并伴有威尔姆斯肿瘤(WT)、泌尿或生殖系统畸形的患者中,也存在于孤立性SRNS患者中。
为进一步评估NS患者中WT1突变的发生率,我们对115例散发性SRNS病例和110例散发性激素敏感型肾病综合征(SSNS)病例作为对照组进行了突变分析。115例散发性SRNS患者中,60例(52%)为男性,55例(48%)为女性。通过单倍型分析验证性别基因型。通过直接测序和变性高效液相色谱(DHPLC)进行突变分析。
在散发性SRNS的3/60(5%)男性(性别基因型)病例和5/55(9%)女性(性别基因型)病例中发现WT1突变,而在110例散发性SSNS病例中未发现(0%)。五名WT1突变女性患者中有一名发生了WT,三名男性患者中有两名伴有泌尿和生殖系统畸形,三名男性患者中有一名出现性反转(女性表型)和双侧性腺母细胞瘤,五名女性患者中有四名患有孤立性SRNS。
根据本研究获得的数据,对于表现为女性表型和SRNS的患者以及表现为生殖器异常的男性患者,应特别进行筛查,以利用有关潜在威尔姆斯肿瘤风险和差异治疗的重要遗传信息。这也将有助于提供更多关于该患者群体表型/基因型相关性的数据。